Core Viewpoint - Lijun Group has established a clear上市计划 for its innovative drugs, with a pipeline of products expected to launch annually starting this year, enhancing its sales growth and revenue structure [1] Group 1: Product Pipeline - The company plans to launch the innovative drug Aripiprazole microspheres in 2025, followed by products in the self-immune field for IL-17A/F psoriasis and ankylosing spondylitis, as well as P-CAB products in the digestive field within the next 2-3 years [1] - In three years, additional products such as NS-041 tablets for mental health, H001 capsules for cardiovascular health, flu vaccines, SG1001 for infections, and newly introduced oral GnRH antagonists are expected to be launched [1] Group 2: Business Stability and Growth - The company's main business remains stable, with multi-sector collaborative development, which will support sales growth as innovative drugs are launched [1] - The proportion of innovative drugs in the revenue structure is expected to increase over time, providing stronger support for overall sales growth [1] Group 3: Additional Product Developments - Besides the first and second category innovative drugs, the company is also developing high-barrier complex formulations and other products that synergize with Lijun, which are expected to launch in the coming years [1] - These include Semaglutide for diabetes and weight loss, recombinant FSH, Leuprolide microspheres (three-month sustained release), and long-acting products in the mental health field, further enhancing the company's growth momentum [1]

Core Viewpoint - Lijun Group (000513) announced on October 27 that it is actively advancing the national negotiation process for the pricing of Aripiprazole microspheres, expecting results within the year, indicating significant future sales potential for long-acting psychiatric products in China [1] Group 1: Market Potential - The penetration rate of long-acting psychiatric formulations in China is currently low, with the clinical usage rate of long-acting antipsychotic injections being less than 1%, compared to an average usage rate of 25%-30% in Europe and the U.S. [1] - The company has initiated various market preparation activities for Aripiprazole microspheres, including forming a nationwide team covering key departments [1] Group 2: Research and Evidence - A real-world evidence study has been launched, covering 60 centers and involving 1,200 patients, to accumulate clinical evidence for Chinese patients [1] - The "Psychiatric Expert Says" column has seen significant growth in followers, effectively reaching different groups from doctors to patients [1] Group 3: Future Outlook - If the national negotiation is successful, it will provide strong support for the volume release of Aripiprazole microspheres and promote the continuous expansion of the long-acting psychiatric formulation market [1]

Core Viewpoint - Lijun Group (000513) is focusing on enhancing its R&D pipeline by introducing multiple products and aims to accelerate clinical transformation through collaboration and acquisition of promising molecules in key therapeutic areas [1] Group 1: R&D Strategy - The company has established a rich R&D pipeline by introducing various products in recent years [1] - Future R&D efforts will concentrate on "strong advantage areas and chronic diseases," including digestive, mental health, cardiovascular, metabolic, and autoimmune diseases [1] - The company emphasizes collaboration to introduce high-potential molecules to support innovative R&D [1] Group 2: Collaboration Focus - Key considerations for collaboration include patent barriers, future commercialization potential, and addressing unmet clinical needs [1] - The company currently holds or shares global market rights for several innovative drug projects, including IL-17A/F, H001 capsules, and a quadrivalent recombinant protein influenza vaccine [1] Group 3: Project Development - The company is actively promoting external licensing collaborations for the IL-17A/F project while engaging with other projects [1] - For early-stage projects, the company plans to accumulate clinical data before advancing business development based on maturity [1]

Core Viewpoint - Lijun Group (000513) focuses on the development of microsphere technology, particularly in the areas of GnRH-α and mental health products, with significant advancements in long-acting formulations and international market expansion [1] Group 1: Product Development - The core product, Leuprolide microsphere (one-month release), is the first GnRH-α long-acting formulation approved by the FDA based on individual drug guidelines [1] - The injectable Triptorelin microsphere has received approval for prostate cancer and is expected to be approved for endometriosis in 2024, with ongoing Phase III clinical trials for central precocious puberty [1] - A three-month release Leuprolide microsphere application has been submitted, with expected approval in 2026 [1] - The company is also developing a microsphere formulation of Ganirelix, which currently has no market presence globally [1] Group 2: Mental Health Product Line - The company has launched an injectable Aripiprazole microsphere, which offers the longest dosing interval (once a month) for schizophrenia treatment globally [1] - Additional products like Brexpiprazole microsphere are in development to strengthen the long-acting product line for mental health [1] Group 3: Market Expansion in Vietnam - The acquisition of Imexpharm in Vietnam is under approval, with the company showing over 20% growth in revenue, profit, and EBITDA in the third quarter [1] - Imexpharm has the largest EU-GMP product line in Vietnam, and both companies are planning product and process transfers to leverage Imexpharm's established market channels and EU-GMP certification for expanding innovative drug products overseas [1]

Core Viewpoint - Lijun Group (000513) reported an increase in sales expenses in Q3, attributed to the market promotion costs for new drugs such as Aripiprazole microspheres and Triptorelin microspheres, indicating a temporary phase rather than a long-term trend [1] Group 1 - The increase in sales expenses is primarily due to the initial market promotion of new drugs [1] - The sales structure changed in Q3, with a significant growth in the formulation drug segment, leading to an increased sales proportion [1] - Overall, the increase in sales expenses is characterized as a short-term fluctuation rather than a trend for the entire year [1]

Core Viewpoint - LIZHU Group has announced the completion of Phase III clinical trials for its LZM012 project targeting psoriasis and ankylosing spondylitis, with key data locked and read out, and plans to submit a formal application for market approval by the end of this year [1] Group 1: Clinical Development - Both indications for LZM012, psoriasis and ankylosing spondylitis, have completed Phase III clinical trials [1] - The key Phase III clinical data has been locked and read out [1] - The company is actively preparing relevant documentation for the upcoming market application [1] Group 2: Regulatory and Market Position - The company has received formal feedback from the CDE, indicating that LZM012 will be prioritized for review [1] - LZM012 is the first domestic Phase III study for psoriasis with PASI100 as the primary endpoint, demonstrating superior efficacy compared to secukinumab [1] Group 3: Business Development - The company is in deep discussions with relevant parties regarding external licensing cooperation details, including due diligence [1] - Any further developments in this area will be announced in a timely manner [1]

Core Viewpoint - LIZHU Group (000513) announced the development of NS-041, a novel highly selective KCNQ2/3 agonist, which is currently the only drug in China conducting clinical research for both epilepsy and depression at this target [1] Group 1: Drug Development - NS-041 has entered Phase II clinical trials for epilepsy, with the first subject enrolled in July 2023 [1] - The IND application for the depression indication has recently been accepted [1] - The drug has been optimized at the molecular structure level to avoid safety issues seen in previous generation drugs targeting the same site, with no potential ocular toxicity risks identified [1] Group 2: Mechanism and Efficacy - NS-041 exhibits better target selectivity, lower off-target risks for related subtypes, and higher lipophilicity, facilitating its passage through the blood-brain barrier [1] - Currently, there are no marketed anti-epileptic drugs targeting the same site globally [1] - In classical acute and chronic depression models in mice, NS-041 demonstrated significant anti-depressant effects [1]

Financial Performance - The company achieved a total revenue of 91.16 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 0.38% [2] - The net profit attributable to the parent company, after deducting non-recurring items, was 4.98 billion yuan, reflecting a year-on-year increase of 17.12% [2] - The formulation segment saw growth in major categories such as digestive, mental health, and traditional Chinese medicine, contributing to overall revenue stability [2] R&D Progress - The company has made significant advancements in key projects, including the submission of the P-CAB tablet for market approval and the completion of Phase II clinical trials for the injection form [3][8] - The IL-17A/F project for psoriasis and ankylosing spondylitis has completed Phase III clinical trials, with data expected to be submitted for market approval by the end of the year [4] - The NS-041 tablet for epilepsy and depression has entered Phase II clinical trials, with promising results in preclinical models [3] Market Strategy - The company plans to leverage its established sales channels in the digestive field to ensure rapid market penetration for new products like JP-1366, which is projected to achieve a sales figure of approximately 12.5 billion yuan in 2024, marking an 81% year-on-year growth [8] - The company is focusing on international expansion, particularly in Vietnam, where it aims to utilize the existing EU-GMP certified product lines of Imexpharm to enhance its market presence [6] Future Outlook - The company anticipates a stable revenue trend for the year, with profit growth expected to outpace revenue growth [11] - A clear roadmap for the launch of innovative drugs has been established, with multiple products set to enter the market over the next few years, including the IL-17A/F project and various formulations in the digestive and mental health sectors [9][10] - The company has committed to a high dividend payout, having repurchased shares worth 17.2 billion yuan and distributed nearly 60 billion yuan in dividends from 2020 to 2024 [13]

Summary of Lizhu Group's Conference Call Company Overview - **Company**: Lizhu Group - **Date**: October 24, 2025 Key Points Financial Performance - **Revenue Growth**: In the first three quarters of 2025, Lizhu Group's revenue increased by 0.38% year-on-year to 6 billion CNY, with a net profit attributable to the parent company (excluding non-recurring items) rising by 4.98% to 17.12 billion CNY [2][4][15] - **Quarterly Performance**: For Q3 2025, the company reported a sales revenue of 28.44 billion CNY, reflecting a 1.6% year-on-year growth [4] - **Segment Performance**: Growth was observed in various formulation categories such as digestive, mental health, reproductive, and traditional Chinese medicine, while the raw material drug segment saw a decline of 5.2% due to weakened downstream demand [2][4] Research and Development - **Product Pipeline**: Lizhu Group has a rich pipeline with several products in various stages of development, including: - PICC GP1,366 tablets submitted for market approval - Interleukin 17 AF for psoriasis expected to be submitted by the end of the year - NS041 for epilepsy entering Phase II trials [2][5][6] - **Innovative Drug Development**: NS041, a novel high-selectivity KCNO 23 agonist, shows promise in both epilepsy and depression indications, with lower adverse reaction rates compared to competitors [8][9] - **Clinical Trials**: Multiple projects are in advanced clinical stages, including H001 anticoagulant and GnIH oral antagonist, indicating a strong focus on enhancing R&D efficiency and international expansion [6][12] Operational Efficiency - **AI Integration**: The company has implemented AI technology across R&D, clinical trials, and sales, leading to a significant reduction in management costs and improved operational efficiency [7] - **Cost Management**: Continuous optimization of management and cost reduction strategies have helped maintain a stable overall expense ratio [7] Market Strategy - **International Expansion**: Lizhu Group is actively pursuing international market opportunities, particularly in Vietnam, leveraging established partnerships and regulatory advantages [11][21] - **Product Diversification**: The company is focusing on a diversified product matrix to mitigate risks associated with market fluctuations and policy changes [16] Future Outlook - **Growth Projections**: The company anticipates stable revenue growth for the full year of 2025, with profit growth expected to outpace revenue growth, supported by innovative drugs [3][15] - **New Product Launches**: A series of innovative drugs are expected to launch over the next three years, contributing significantly to sales growth and enhancing the overall revenue structure [14][15] Shareholder Returns - **Dividend Policy**: Lizhu Group has a strong commitment to shareholder returns, with a history of significant buybacks and dividends, totaling 60 billion CNY over the past five years [17][21] Quality Assurance - **Quality Control**: The company emphasizes stringent quality standards in both generic and innovative drug production, ensuring high-quality outcomes through rigorous R&D and manufacturing processes [22] Sales and Marketing - **Sales Strategy**: Increased sales expenses in Q3 were attributed to initial marketing costs for new drugs, which are expected to be a short-term impact rather than a long-term trend [20][21] This summary encapsulates the key insights from Lizhu Group's conference call, highlighting its financial performance, R&D advancements, operational strategies, market outlook, and commitment to quality and shareholder returns.

Core Insights - The company reported a total revenue of 9.116 billion yuan and a net profit attributable to shareholders of 1.754 billion yuan for Q3 2025 [1] - The operating cash flow net inflow was 2.525 billion yuan [1] Financial Metrics - The latest debt-to-asset ratio stands at 37.37% [3] - The gross profit margin is reported at 66.39% [3] - The return on equity (ROE) is 12.56% [3] - The diluted earnings per share (EPS) is 1.96 yuan [3] - The total asset turnover ratio is 0.37 times [3] - The inventory turnover ratio is 1.68 times [3] Shareholder Information - The number of shareholders is 47,400, with the top ten shareholders holding a total of 5.98 billion shares, accounting for 66.15% of the total share capital [3] - The largest shareholder is Hong Kong Central Clearing (Agent) Co., Ltd., holding 33.0% [3] - Health元药业集团股份有限公司 is the second-largest shareholder with 24.4% [3]